Skip to main content
Toggle navigation
Login
Search
Home
Browse by Poster Title
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
NUM
Sort by
Title
T
Favorite
024
The Drug-Drug Interaction Effect of Steady State Rifampin Exposure on Single Dose Pharmacokinetics of Lazertinib
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
032
The Effect of an Acid-reducing Agent, Esomeprazole on Sparsentan Pharmacokinetics in Healthy Volunteers
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
054
The Effect of Moderate Hepatic Impairment on ONC201 (Dordaviprone) Pharmacokinetics
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
143
The Effect of Severe Renal Impairment on ONC201 (Dordaviprone) Pharmacokinetics
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
115
The Effectiveness of Anmarin, an Antimycotic Herbal Drug: Preclinical & Clinical Studies
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
150
The Gut-immune-liver Axis in Patients With Alcohol Use Disorder & Clinically Low Serum Zinc Levels
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
155
The Human Metabolism of Lufotrelvir, a Prodrug for the Treatment of SARS-COV2, Investigated By LC+AMS
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
089
The Impact of COVID-19 Mediated Bidirectional Dysregulation of CYP3A4 on Systemic & Pulmonary Candidate Drug Concentrations
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
067
The Impact of Late-Runner Participants on PK Variability in Healthy Volunteer, Single-Ascending Dose Trials
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
148
The Mechanism of Action of an Innovative Respiratory Stimulant, ENA-001
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
101
The SARS-CoV-2 Mpro Inhibitor Ibuzatrelvir is a Substrate but not an Inducer nor Inhibitor of CYP3A
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
093
Trends in First-in-Human Trials of Intrathecal Antisense Oligonucleotide Therapies: Insights into Dose Selection, Dose Escalation & Early Clinical Development
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
